BioLineRx to Report Second Quarter 2014 Results on August 6, 2014
Management to hold a conference call at
The Company will host a conference call on
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will be available until
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s ‘SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes
Source: BioLineRx
Tiberend
Strategic Advisors, Inc.
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Andrew
Mielach, 212-375-2694
amielach@tiberend.com
or
BioLineRx
Tsipi
Haitovsky, +972-3-6240871
Public Relations
tsipihai5@gmail.com